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Abstract 
Background: Lung cancer is one of the most preventable causes of death globally both in developed and develop-
ing countries. Although it is well established that smokers develop lung cancer, there are some smokers who are free 
from the disease risk. The predisposition to lung cancer is attributed to genetic polymorphisms in xenobiotic metabo-
lizing genes. Reports on assessment of xenobiotic metabolizing genes like Cytochrome P 450 1A1 (CYP1A1), Glutathione 
-S -transferase M1 (GSTM1) and T1 (GSTT1) polymorphisms from India are meagre, and reports from Andhra Pradesh are 
lacking.
Methods and results: Assessment of polymorphisms in CYP1A1, GSTM1 and GSTT1 in NSCLC patients and healthy 
individuals specific to population of Andhra Pradesh, a South Indian state was attempted by multiplex PCR and RFLP, 
and this is the first study which tried to correlate oxidative stress with the polymorphisms in xenobiotic metaboliz-
ing genes. Results showed that CYP1A1 m1 ‘CC’ genotype was significantly associated with lung cancer susceptibility 
with a 2.3-fold risk, CYP1A1 m2 ‘AG’ gene polymorphisms with 8.8-fold risk and GSTT1 (−/−) genotype demonstrated a 
twofold risk of disease susceptibility.
Conclusions: A combined role of genetic polymorphisms and smoking status can be attributed for the cause of lung 
cancer. Further, the association between oxidative stress and genetic polymorphisms showed a correlation between 
GSTT1 and super oxide dismutase activity; CYP1A1 m1, m2 and GSTT1 with glutathione peroxidase activity; CYP1A1 
m1 and GSTM1 with melondialdehyde levels; and CYP1A1 m1 and GSTT1 with 8-oxo-7,8-dihydro-2′-deoxyguanosine. 
A higher risk of lung cancer seems to be associated with combined gene polymorphisms of phase I and phase II 
enzymes than that ascribed to single gene polymorphism.
© 2016 Peddireddy et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Xenobiotic metabolism is the process of detoxification 
of endogenous or exogenous carcinogens/poisons and 
occurs in two phases. In Phase I, cytochrome P450 oxi-
dases amend the xenobiotics by introducing a polar 
or reactive group. In Phase II, the modified xenobiot-
ics are conjugated to polar compounds facilitated by 
enzymes such as glutathione S-transferases [1]. Among 
the phase I enzymes, cytochrome P450 1A1 (CYP1A1) 
plays a vital role in the activation of polycyclic aromatic 
hydrocarbons (PAHs) to convert them to carcinogens 
[2]. The phase II enzymes involve glutathione-S-trans-
ferases (GSTs) which are divided into five classes (alpha, 
mu, pi, theta and zeta), and catalyse the conjugation of 
highly reactive PAHs to soluble glutathiones [3]. Among 
the GSTs, GSTM1 preferentially detoxifies carcinogens 
(epoxides and hydroxylated derivatives) derived from 
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of many toxins such as butadiene and ethylene oxides 
(ingredients of tobacco smoke) [4]. The balance between 
the phase I and phase II enzymes is crucial to determine 
the amount of reactive intermediates that are formed in 
the cell. Any aberrations due to genetic polymorphisms 
affect the activities of these enzymes; thereby, increasing 
the risk of cancer in an individual and gene–gene interac-
tions of phase I and phase II enzymes together with life 
style habits can be synergistic risk factors.
Among all the cancers, carcinoma of the lung is 
responsible for the high death rate throughout the world 
[5]. Although tobacco consumption is considered to be 
the significant aetiological factor for lung cancer [6], not 
all smokers develop lung cancer. Risk is dependent on the 
extent of smoking, environmental factors (carcinogen 
exposure) and most prominently genetic factors. Genetic 
polymorphisms in the enzymes involved in metabolic 
activation and detoxification were found to immensely 
contribute to the risk of developing lung cancer [7]. These 
polymorphisms cause inter-individual differences in the 
bio-activation and detoxification of pro-carcinogens, 
which are in turn responsible for the varied susceptibili-
ties to lung cancer [8, 9]. Among the xenobiotic metabo-
lizing enzymes, CYP1A1, GSTM1 and GSTT1 have been 
projected as the potential modulators of cancer suscep-
tibility [10]. Although these enzymes play a crucial role 
in bio-activation and detoxification of chemical carcino-
gens present in tobacco smoke, the role of Glutathione–
S transferase genes in modulating the risk of cancer has 
been debated owing to inter-individual, geographical, 
ethnic and demographical differences throughout the 
world. The association between CYP1A1 and GSTM1 
polymorphisms in lung cancer was reported [11, 12]. 
However, GSTT1 deficiency was demonstrated (GSTT1 
null) not to increase the risk of lung cancer [13, 14]. 
The frequencies of CYP1A1 and GSTM1 gene polymor-
phisms were found to vary among different ethnic popu-
lations [15, 16]. Among Asians, CYP1A1 2A and CYP1A1 
2C genetic polymorphisms are common, whereas in Cau-
casians, the variation in CYP1A1 2C is rare [16, 17]. Simi-
larly, GSTM1 null type is more common in Asians than in 
Caucasians [18]. Null genotype represents the homozy-
gous deletion of the gene. The inter-relation between 
CYP1A1 polymorphism, tobacco smoking and lung can-
cer was found to be high in Japanese and Chinese popula-
tions, whereas the same was not observed in Caucasians 
[17, 19–22]. The risk association between GSTM1 null 
genotype with squamous cell and small cell carcinomas 
in Asians was found to be significant [23, 24]. Further, a 
combination of GSTM1 null genotype with CYP1A1 pol-
ymorphisms augmented lung cancer risk [25, 26].
In the Indian context, studies on association of 
lung cancer and genetic polymorphisms are limited. 
In a North Indian cohort, the risk of CYP1A1 gene 
polymorphism in 100 patients with lung cancer was 
assessed, and a 2.68-fold risk was observed for CYP1A1 
2C allele and in the presence of a single copy of the 
variant CYP1A1 (CYP1A1 * 1/2A) and for null GSTT1 
genes, a threefold increased risk of lung cancer was 
demonstrated [27]. Another group from North India 
demonstrated that the risk of lung cancer is associ-
ated with CYP1B1 and GSTM1 polymorphisms in the 
population [28]. CYP2E1 polymorphisms in six ethnic 
groups of South Indian population were demonstrated 
[29]. A study from Kerala in 146 lung cancer patients 
indicated that CYP1A1 MspI homozygous variant allele 
and GSTT1 null deletion frequency were significantly 
higher in smoking-induced lung cancer patients com-
pared with other populations [30]. The Southern part 
of India is largely composed of five states, namely, 
Andhra Pradesh (Telangana + Andhra Pradesh), Tamil-
nadu, Kerala, Karnataka and Maharashtra, where the 
environmental conditions, economy, food habits and 
life style vary a lot. The limitations of systematic stud-
ies that correlate the association between CYP450 and 
GST gene polymorphisms and the risk of lung cancer 
include (1) limited number of subjects from different 
areas which are not representative of the entire popu-
lation; (2) subjects exposed to different environmental 
conditions; and (3) different gene polymorphisms being 
evaluated. Besides ethnic background, life style and 
dietary habits also contribute to the increased risk of 
lung cancer. The dietary habits, environmental factors 
and tobacco consumption vary between the Northern 
and Southern regions of India. Tobacco consumption 
is rampant in both North and South Indian popula-
tions [31]. Although studies reported the association of 
lung cancer and gene polymorphisms in South Indian 
population, the samples were drawn from a tertiary 
hospital located in the capital city of a particular state. 
Hence, the entire South Indian population was not rep-
resented. In view of the above, it becomes imperative 
to determine the association between the gene poly-
morphisms of enzymes that are associated with detoxi-
fication of tobacco-related carcinogens and the risk of 
lung cancer in the state of Andhra Pradesh to gener-
ate more data to arrive at a plausible conclusion. Fur-
ther, the samples were collected from a single hospital 
that received patients from the entire state of Andhra 
Pradesh, and this ensured homogeneity of the samples 
obtained.
Besides genetic factors, biochemical markers such 
as oxidative stress and antioxidant responses were also 
implicated in the development of lung cancer which 
showed changes in the oxidant and antioxidant statuses 
in the peripheral lymphocytes of non-small cell lung 
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cancer (NSCLC) patients [32]. However, till date, stud-
ies that demonstrate the association between genetic and 
biochemical interactions and the risk of NSCLC were not 
reported. Hence, for the first time, in this study, we ana-
lysed such associations which might serve as predictive 
markers, contributing to differential susceptibility toward 
PAH and tobacco-induced cancers.
Methods
Study population
The subjects of the present study included 246 newly 
diagnosed and previously untreated NSCLC patients 
referred to Indo-American cancer Hospital from vari-
ous regions of Andhra Pradesh, India during the period 
June 2008–2012. 98.2 % of the patients and all the control 
subjects included in our study were natives of Andhra 
Pradesh. All the patients were rated as positive for 
NSCLC by histological analyses and were classified using 
revised lung cancer staging system [33]. The co-morbid 
conditions in NSCLC patients included 24 (9.75  %) of 
them being diabetic, 30 (12.19  %) hypertensive and 2 
(0.81  %) patients having hypothyroidism. Age- and sex-
matched healthy controls (n  =  250) were enroled from 
the general population of the same geographical region. 
Routine medical check-up was conducted, and history 
of illness was recorded by a health practitioner. Those 
who appeared apparently healthy without any history of 
cancer or other chronic diseases were considered as nor-
mal. The co-morbid conditions among controls included 
8 (3.2 %) of them being diabetic, 11 (4.4 %) being hyper-
tensive, and none having hypothyroidism. Study subjects 
who were used to smoking at the time of diagnosis were 
considered as smokers and those who had smoked at 
least 100 cigarettes in their life time were considered as 
ex-smokers. Among the NSCLC smokers, 51 (48.11  %) 
and 47 (44.34 %) consumed cigarettes and bidis, respec-
tively, and 8 (7.55  %) consumed both. In the case of 
NSCLC patients who are ex-smokers, the cigarette and 
bidi consumers were 26 (61.9  %) and 15 (35.72  %), and 
1 (2.38 %) consumed both bidi as well as cigarette. Pack 
years were computed as the number of cigarettes smoked 
per day multiplied by the duration of smoking in years, 
and the average tobacco consumption was expressed in 
pack years. Among the control smokers, 48 (76.19  %) 
consumed cigarettes, while 15 (23.81 %) were bidi smok-
ers. In case of ex-smokers, 8 (66.66  %) were cigarette 
smokers, while 4 (33.34 %) were bidi smokers.
Ethics statement
The study was carried out with the approval of Institu-
tional Ethics Committees of Indo-American Cancer Hos-
pital and Institute of Genetics and Hospital for Genetic 
Diseases. Educated and informed consent was obtained 
from all the subjects of the study. A standard question-
naire was used to document the socio-demographical 
characteristics such as age, sex, lifestyle (alcohol, diet, 
etc.), occupational exposure (working hours/day, years 
of exposure, use of protective measures, etc.), history of 
smoking, number of cigarettes per day and duration of 
smoking.
Molecular analysis of CYP1A1 m1, m2, GSTM1 and GSTT1 
gene polymorphisms
Blood collection and DNA isolation
2  ml of whole blood was collected in vacutainers (BD 
Biosciences) containing ethylenediamine tetra acetic 
acid (EDTA) for DNA isolation, and 3  ml was collected 
in heparinized vacutainers for the assessment of oxida-
tive stress markers from healthy controls and NSCLC 
patients. Genomic DNA was isolated (Flexi gene extrac-
tion kit, QIAGEN) from 300 μl of whole blood and was 
stored in −80 °C until further use.
CYP1A1 m1 and m2 genotyping
Genotyping for CYP1A1 m1 and m2 genes (rs4646903 
and rs1048943) was carried out as described earlier 
[34]. The primers’ sequences used for m1 site were M1F 
(5′-CAG TGA AGA GGT GTA GCC GCT-3′) and M1R 
(5′-TAG GAG TCT TGT CTC ATG CCT-3′) and for 
m2 site were M2F (5′- TTC CAC CCG TTG CAG GAT 
AGC C-3′) and M2R (5′-CTG TCT CCC TCT GGT 
TAC AGG AAG-3′). The PCR amplification was carried 
out in 25-µl reaction mixture consisting of 100 ng tem-
plate of DNA, 10 µM of each primer, 0.2 mM each dNTP, 
2.4 mM MgCl2, 1 U Taq DNA polymerase with 1× reac-
tion buffer (Bangalore Genei). The PCR cycle consisted of 
1  min at 94  °C, 1  min at 61  °C (for CYP1A1 m1)/63  °C 
(for CYP1A1 m2) and 1  min at 72  °C with initial dena-
turation of 5 min at 94 °C and final extension of 10 min 
at 72 °C. The PCR amplicons generated for m1 (340 bp) 
and m2 (204 bp) were subjected to restriction digestion. 
Msp1 and BsrD1 restriction enzymes were used to detect 
polymorphisms in the CYP1A1 m1 and m2, respectively. 
The reaction mixtures were incubated at 37  °C for 12 h, 
electrophoresed on 3.0  % agarose gel and stained with 
ethidium bromide (Sigma Aldrich, USA) for visualiza-
tion. All the sampling experiments were done in dupli-
cates. Restriction digestion was repeated in cases which 
were unclear. Positive samples were included in each run 
of PCR as well as restriction digestion to ensure that the 
samples were properly digested.
GSTM1 and GSTT1 genotyping
The GSTM1 and GSTT1 gene deletions (rs4025935 and 
rs71748309) were analysed simultaneously by mul-
tiplex PCR [35]. To detect the GSTM1 deletion, the 
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primers used were GSTM1 F (5′-GAACTCCCTGAAAAG 
CTAAAGC-3′) and GSTM1 R (5′-GTTGGGCTC 
AAATATACGGTGG-3′). For GSTT1, the primers 
used were GSTT1 F (5′-TTCCTTACTGGTCCTCAC 
ATCTC-3′) and GSTT1R (5′-TCACCGGATCATGGCC 
AGCA-3′). The PCR amplicons were electrophoresed on 
a 4  % agarose gel, stained with ethidium bromide, and 
the results were documented using a gel documentation 
system (Bio-Rad). The presence of GSTM1 and that of 
GSTT1 genes were indicated by the resulting 215- and 
480-bp PCR amplicons, respectively. A DNA sample with 
GSTM1 and GSTT1 alleles present was run as a positive 
control in each run. As an internal control, human albu-
min gene (HAB) was amplified (350 bp) using the prim-
ers HAB F (5′-CAACTTCATCCACGTTCACC-3′) and 
HAB R (5′-GAAGAGCCAAGGACAG GTAC-3′) for the 
authentication of multiplex PCR.
Estimation of 8‑oxodG, lipid peroxidation and antioxidant 
enzymes
8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) lev-
els in the urine samples of healthy controls and NSCLC 
patients were measured in 125 patients and 100 controls 
using commercially available kits (Japan Institute for the 
Control of Aging, Shizuoka, Japan). Lipid peroxidation 
products were measured in the plasma of 246 patients 
and 250 controls as described earlier [32]. Red cell 
superoxide dismutase (SOD) and glutathione peroxidase 
(GPx) activities were estimated in 238 NSCLC patients 
and 250 controls using SOD-525 and GPx-340 spectro-
photometric assay kits according to the manufacturer’s 
instructions (Bioxytech; OXIS International, Portland, 
USA). Haemoglobin (Hb) concentrations were measured 
by a commercially available kit (Sigma, St. Louis, MO, 
USA).
Statistical analyses
The data were analysed using the SPSS 15.0 program 
(SPSS, Chicago, IL). The significance of the differences 
between controls and patients end point means were 
analysed using Student’s t test. ANOVA (analysis of vari-
ance) was used for comparisons among the three or more 
groups. Multiple regression analysis was done to investi-
gate the associations of the independent variables. Pear-
son correlation analysis was used for testing relationships 
between genotypes in patients and controls. The results 
were considered to be significant at p values of less than 
0.05 (indicated by *). The differences in the distribu-
tion of genotype frequencies were calculated using the 
χ2 test. Genotype frequencies were checked for devia-
tion from Hardy–Weinberg equilibrium and were not 
significantly different from those predicted. Odds ratios 
and 95  % confidence interval (95  % CI) were calculated 
to assess the relationship between CYP1A1 and GST gene 
polymorphisms.
Results
General characteristic features of the study group
The general characteristic features of NSCLC patients 
(n = 246) who had no previous history of diagnosis and 
healthy controls (n  =  250) included in this study are 
given in Table  1. NSCLC was predominant in males, 
affecting older men in the age group of 60–70 years. Age 
of onset of the disease was lower in women compared to 
males (55 vs. 58.91), although it was not statistically sig-
nificant. The risk estimation for patients without co-mor-
bid conditions compared to controls without co-morbid 
conditions was 3.58-fold (OR 3.58; 95  % CI 2.058, 6.24; 
p ≤ 0.001).
Molecular analysis of CYP1A1 m1, m2, GSTM1 and GSTT1 
genes
CYP1A1m1 and m2 polymorphisms were detected by 
RFLP. PCR amplification for CYP1A1 m1 produces 
340-bp amplicons. A gain of Msp1 restriction site in 
Table 1 General characteristics of the study group
* p < 0.05






 Male 177 (71.95) 180 (73.91) 0.99
 Female 69 (28.05) 70 (26.09) 0.99
Age
 Mean ± (SD) 57.57 ± 10.19 58.06 ± 9.56
Stages of NSCLC
 II 28 (7.66)
 III 82 (34.23)
 IV 136 (58.11)
Histology
 Squamous-cell  
carcinoma
97 (43.24)
 Adenocarcinoma 109 (48.65)
 Large cell and others 40 (8.11)
Alcoholism
 Consumers 95 (38.62)* 26 (10.4) 0.01
 Non-consumers 151 (61.38)* 224 (89.6) 0.01
Smoking status
 Never-smokers 98 (39.84)* 175 (69.08) <0.001
 Ex-smokers 42 (17.07)* 12 (4.35) <0.001
 Current smokers 106 (43.08) * 63 (26.57) <0.001
 ≤20 pack years 38 (15.45) 28 (11.2) 0.16
 21–40 pack years 34 (13.82)* 18 (7.2) 0.01
 41–60 pack years 8 (3.25) 5 (18.85) 0.38
 >60 pack years 26 (10.57)* 12 (7.72) 0.01
 Passive smokers 38 (15.45)* 5 (2) <0.001
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the polymorphic allele resulted in 340-bp products 
for homozygous major type (TT), 200 and 140  bp for 
homozygous minor (CC), respectively (Fig.  1). BsrD1 
restriction enzyme-based digestion was used to detect 
the CYP1A1m2 polymorphisms. In the case of ‘GG’ 
(homozygous minor), due to loss of the restriction sites, 
a single amplicon of 204 bp was obtained, whereas in the 
‘AA’ (homozygous major) allele will generate two ampli-
cons of sizes, 149 and 55  bp (Fig.  2). Multiplex PCR-
based approach was employed to determine the genetic 
polymorphisms of GSTM1 and GSTT1 genes. Amplicons 
of 215 bp and 480 bp indicated the presence of GSTM1 
and GSTT1 genes (Fig. 3).
Genotyping distribution of CYP1A1 m1 (T3801C 3′ 
noncoding region)
The homozygous major (TT), heterozygous (TC) and 
homozygous minor (CC) genotype frequencies of 
CYP1A1 m1 gene in healthy controls were 57.2, 37.2 and 
5.6 %, respectively, whereas the same in NSCLC patients 
were 49.59, 38.62 and 11.78 %, respectively (Table 2). The 
‘CC’ genotype was significantly higher in the NSCLC 
patients compared to healthy controls (p  =  0.007, 
χ2 = 5.98, OR 2.25, 95 % CI 1.16–4.37) with 2.25-fold risk 
of disease susceptibility.
Genotyping distribution of CYP1A1 m2 (Exon 7 Ile462Val)
The frequencies of CYP1A1 m2 homozygous major (AA), 
heterozygous (AG) and homozygous minor (GG) geno-
types in healthy controls were 78.4, 13.6 and 8 %, whereas 
the same were 29.67, 58.14 and 12.19 % in NSCLC patients, 
respectively (Table 3). Interestingly, the heterozygous ‘AG’ 
genotype was significantly higher in NSCLC group com-
pared to healthy controls (p < 0.001, χ2 = 106.9, OR 8.82, 
95  % CI 5.67–13.72) with an estimated 8.8-fold risk of 
developing lung cancer in individuals with this genotype.
Fig. 1 Amplifications of CYP1A1 m1 and the RFLP products of 
the polymorphic forms: a PCR for CYP1A1 m1 (340 bp) in multiple 
samples. b CYP1A1 m1 polymorphisms were detected by RFLP. The 
340-bp PCR product was digested with Msp1 enzyme. Lanes 4 and 
9 represent homozygous major type (TT; 340 bp); Lanes 3 and 12 
represent homozygous minor (CC; 200 and 140 bp); Lanes 1, 2, 5, 6, 7, 
8, 10, 11, 13, 14 and 15 represent heterozygous type (TC; 340 bp, 200 
and 140 bp)
Fig. 2 Amplifications of CYP1A1 m2 and the RFLP products of the 
polymorphic forms: a PCR amplification for CYP1A1 m2 (204 bp). b 
CYP1A1 m2 polymorphism detected by RFLP. The 204-bp PCR product 
was digested with BsrDI enzyme. The cleavage site is lost in case of 
variants to give a single amplicon, whereas the wild-type allele gener-
ates 149- and 55-bp fragments. Lane 5 represents homozygous minor 
(GG); Lane 7 represents the heterozygote (AG); Lanes 2–4, 6 and 8–13 
represent homozygous major (AA)
Fig. 3 GSTM1 and GSTT1 polymorphisms: The GSTM1 and GSTT1 
gene deletions were analysed simultaneously by multiplex PCR. 
Amplicons of 215 bp and 480 bp indicate, respectively, GSTM1 and 
GSTT1. Lane 1, 100-bp DNA ladder; Lanes 2 and 14, GSTT1 Null type 
(TN); Lanes 3–13 and 15–18: GSTT1 Wild type (TW); Lanes 2–9 and 
13–18: GSTM1 wild type (MW); Lanes 10–12: GSTM1 Null type (MN). 
Albumin (350 bp) was used as an internal control
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Risk associated with additive effect of CYP1A1 m1 
and CYP1A1 m2 polymorphisms within the same gene
Healthy controls displayed higher percentage of homozy-
gous major (TT/AA) genotype combination (44.8  %) 
followed by the combination of homo/hetero (TT/AG; 
38  %), and hetero/homo (TC/AA; 29.2  %), among all 
SNP combinations (Additional file 1: Table S1). Interest-
ingly, in NSCLC patients, the frequency of homo/hetero 
genotypes and hetero/homo (TT/AG; 29.26  % and TC/
AA; 14.63  %) was more common, followed by homozy-
gous major (TT/AA; 13.41 %) genotypes. The frequency 
of homozygous minor genotype ‘CC/GG’ (p  =  0.02, 
χ2 = 4.79, OR 12.48, CI 0.69–224.5) in patients demon-
strated a 12-fold risk of developing lung cancer compared 
to the controls. The combination of ‘CC/AG’ (p = 0.004, 
χ2 = 6.89, OR 6.89, CI 2.01–23.6) showed a 6.9-fold risk 
of susceptibility to lung cancer, while heterozygous m1/
m2 ‘TC/AG’ (p =  0.001, χ2 =  28.33, OR 5.18, CI 2.69–
10.00) presented with a five fold risk.
Genotypic distributions of GSTM1 and GSTT1 genes
GSTM1 gene was found to be present in 76  % of the 
healthy controls and 73.98  % of NSCLC patients 
(Table 4). GSTT1 gene was present in 89.6 % of healthy 
controls and 81.3  % of NSCLC patients and individuals 
lacking this gene were at a twofold risk of developing 
lung cancer (p = 0.008, χ2 = 6.86, OR 1.98, CI 1.18–3.32) 
(Table 5).
Table 2 Genotype and  allelic distributions of  the CYP1A1 m1 gene polymorphisms in  NSCLC patients and  healthy con-
trols
* p < 0.05
Genotype/Allele Lung cancer (n = 246) Controls (n = 250) χ2 OR (95 % CI) p value
N (%) N (%)
TT 122 (49.59) 143 (57.2) 1 Reference
TC 95 (38.62) 93 (37.2) 0.10 1.06 (0.73, 1.55) 0.42
CC 29 (11.78) 14 (5.6) 5.98 2.25 (1.16, 4.37) 0.007*
Table 3 Genotype and allelic distribution of the CYP1A1 m2 gene polymorphisms in NSCLC patients and healthy controls
* p < 0.05
Genotype/Allele Lung cancer (n = 246) Controls (n = 250) χ2 OR (95 % CI) p value
N (%) N (%)
AA 73 (29.67) 196 (78.4) 1 Reference
AG 143 (58.14) 34 (13.6) 106.9 8.82 (5.67, 13.72) 0.001*
GG 30 (12.19) 20 (8) 2.43 1.59 (0.88, 2.89) 0.12
Table 4 Genotype distribution of the GSTM1 gene polymorphism in NSCLC patients and healthy controls
* p < 0.05
Genotype Lung cancer (n = 246) Controls (n = 250) χ2 OR (95 % CI) p value
N (%) N (%)
GSTM1 (+/+) 182 (73.98) 187 (76.0) 1 Reference
GSTM1 (−/−) 64 (26.1) 63 (24.0) 0.04 1.04 (0.69, 1.56) 0.83
Table 5 Genotype distribution of the GSTT1 gene polymorphism in NSCLC patients and healthy controls
* p < 0.05
Genotype Lung cancer (n = 226) Controls (n = 210) χ2 OR (95 % CI) p value
N (%) N (%)
GSTT1 (+/+) 200 (81.30) 224 (89.6) 1 Reference
GSTT1 (−/−) 46 (18.69) 26 (10.4) 6.86 1.98 (1.18, 3.32) 0.008*
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Risk associated with combination of the two 
glutathione‑S‑transferase gene polymorphisms
Combined frequencies of GSTM1 and GSTT1 polymor-
phisms Wild/Wild, Wild/Null, Null/Wild and Null/Null 
in healthy control were 66.80, 10.40, 23.60 and 1.6  %, 
respectively, whereas in NSCLC patients the frequencies 
were 59.34, 14.63, 21.95 and 4.06 %, respectively. It was 
clear that the GSTM1 Wild/GSTT1 Wild genotype fol-
lowed by GSTM1 Null/GSTT1 Wild combinations were 
more predominant in both healthy controls and NSCLC 
patients (Additional file 1: Table S2). The disease associa-
tion was found between GSTM1 Wild/GSTT1 Null geno-
type (p = 0.01, OR 1.97) and GSTM1 Null/GSTT1 Null 
(p = 0.04, OR 2.6) combinations, indicating a 1.97- and 
2.6-fold risk of disease susceptibility, respectively (Addi-
tional file 1: Table S2).
Risk of NSCLC associated with CYP1A1, GSTM1 and GSTT1 
genotypes stratified by smoking exposure
Patients who were non-smokers and having a CYP1A1 
m1 (T/C) (OR 1.82, 95 % CI 1.08, 3.07) and CYP1A1 m2 
(A/G) (OR 12.39 95 % CI 6.53, 23.51) genotypes had an 
increased lung cancer. Lung cancer patients who smoked 
and having CYP1A1 m1 T/C, C/C and CYP1A1 m2 A/G, 
G/G and GSTT1 null (−/−) genotypes were at higher 
risk compared to the controls (Table 6).
Association of CYP1A1, GSTM1 and GSTT1 genotypes 
stratified by histology
In all the three pathological subtypes, CYP1A1m2 A/G, 
GSTM1 (+/+) wild and GSTT1 (+/+) wild were the pre-
dominant genotypes (Table 7).
Risk of NSCLC associations with combination of CYP1A1 
and GST genes
The combinations of genotypes having a profound effect 
were CYP1A1 m2 A/G + GSTM1 wild (+/+); CYP1A1 m2 
A/G + GSTM1 null (−/−); and CYP1A1 m2 G/G + GSTT1 
wild (+/+) with estimated risks of sixfold, sixfold and 10.5-
fold, respectively (Additional file 1: Table S3).
In the case of three genotype combinations, CYP1A1 
m1 T/T  +  CYP1A1 m2 G/G  +  GSTM1 null (−/−) 
showed a 19-fold risk; CYP1A1 m1 T/C + CYP1A1 m2 
G/G  +  GSTM1 wild (+/+) showed 11.6-fold risk and 
CYP1A1 m1 G/G  +  CYP1A1 m2 A/G  +  GSTM1 wild 
(+/+) showed a 10.5-fold risk of disease susceptibility 
(Additional file 1: Table S4).
The overall risk of NSCLC associated with three geno-
type combinations of CYP1A1 m1, m2 and/or GSTT1 
genes ranged from 3.48 to 10.55 (Additional file 1: Tables 
S5, S6). When analysed for the overall risk with four 
genotype combinations, it ranged from 5.22 to 13.89 
(Additional file  1: Tables S7–S9). Spearman coefficient 
correlation indicated CYP1A1 m2 gene significantly cor-
related with GSTM1 and GSTT1 genes (Table 8).
Impact of gene polymorphisms on oxidative stress markers
The impact of CYP1A1 m1, CYP1A1m2, GSTM1 
and GSTT1 gene polymorphisms on superoxide dis-
mutase activity (Table  9), Glutathione peroxidase activ-
ity (Table  10), MDA (Table  11) and 8-OHdG levels 
(Table  12) were assessed between controls and lung 
cancer patients. In NSCLC patients, there was a signifi-
cant difference between the SOD levels of GSTT1 wild 
(+/+) vs null (−/−); GPx activities between CYP1A1 
Table 6 Risk of NSCLC associated with CYP1A1 m1, m2, GSTM1, GSTT1 genotypes stratified by smoking exposure
* p < 0.05
# Yates corrected Chi square
Variables smoking  
status
Cases/ controls  
non‑smokers 98/175
OR (95 % CI)  
non‑smokers
p Cases/ controls  
smokers 148/75
OR (95 % CI)  
smokers
p value
CYP1A1m1 (T/T) 49/115 0.52 (0.31, 0.86) 0.01 63/58 0.21 (0.11, 0.40) <0.001
CYP1A1m1 (T/C) 40/48 1.82 (1.08, 3.07) 0.02* 70/15 3.59 (1.87, 6.88) <0.001*
CYP1A1m1 (C/C) 9/12 1.37 (0.56, 3.38) 0.48 15/2 4.11 (0.91,18.5) 0.04*,#
CYP1A1m2 (A/A) 33/142 0.11 (0.06, 0.20) 0.001 40/54 0.14 (0.07, 0.26) <0.001
CYP1A1m2 (A/G) 56/17 12.39 (6.53, 23.51) 0.001* 87/17 4.86 (2.58, 9.15) <0.001*
CYP1A1m2 (G/G) 9/16 1.05 (0.42, 2.36) 0.99 21/4 2.93 (0.96, 8.88) 0.04*,#
GSTM1 (+/+) 76/133 1.09 (0.60, 1.96) 0.77 106/54 0.98 (0.52, 1.82) 0.95
GSTM1 (−/−) 22/42 0.92 (0.51, 1.65) 0.77 42/21 1.01 (0.54, 1.89) 0.95
GSTT1 (+/+) 89/158 1.06 (0.45, 2.48) 0.88 111/66 0.40 (0.18, 0.90) 0.02
GSTT1 (-/-) 9/17 0.93 (0.40, 2.19) 0.88 37/9 2.44 (1.11, 5.38) 0.02*
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m1 T/T vs T/C and T/T vs C/C; CYP1A1 m2 A/A vs 
A/G and A/A vs G/G genotypes and GSTT1 wild vs null 
genotypes. Mean MDA levels were significantly different 
with respect to CYP1A1 m1 and GSTM1 genotypes. The 
difference in 8-OHdG levels between the genotypes was 
significant only for CYP1A1 m2 gene and GSTT1 gene 
polymorphisms. The difference between the genotypes of 
different genes for SOD, GPx, MDA and 8-OHdG levels 
were not significant in the control group.
Multiple regression analysis of different variants in lung 
cancer patients
Multiple regression analysis was performed by tak-
ing age, gender, smoking status, alcohol consump-
tion, dietary habits, occupation, family history, stage 
of the disease and histology (Table  13). We observed 
that smoking, histology, stage of the disease, MDA lev-
els, GPx activities and polymorphisms in CYP1A1 m1 
and GSTT1 genes were the strongest predicting factors 
for increased free radical generation and imbalances in 
antioxidant defence causing oxidative stress and leading 
to disease susceptibility in lung cancer patients. Other 
variables did not have any impact as reflected by lack of 
significance.
Table 7 Genotypic distributions of CYP1A1 m1, m2, GSTM1, GSTT1 stratified by histology of NSCLC
Genotype Squamous % Adeno % Large + others %
CYP1A1m1 (T/T) 45 46.4 48 44 12 30 
CYP1A1m1 (T/C) 46 47.4 52 47.7 21 52.5 
CYP1A1m1 (C/C) 6 6.2 9 8.3 7 17.5 
CYP1A1m2 (A/A) 25 25.8 37 33.9 11 27.5 
CYP1A1m2 (A/G) 62 63.9 56 51.4 25 62.5 
CYP1A1m2 (G/G) 10 10.3 16 14.7 4 10 
GSTM1 (+/+) 69 71.1 80 73.4 33 82.5 
GSTM1 (−/−) 28 28.9 29 26.6 7 17.5 
GSTT1 (+/+) 78 80.4 88 80.7 34 85 
GSTT1 (−/−) 19 19.6 21 19.3 6 15 
Table 8 Spearman correlation coefficients between  geno-
types in NSCLC patients and healthy controls
a Correlation is significant at the 0.05 level (2-tailed)
b Correlation is significant at the 0.01 level (2-tailed)
CYP1A1m1 CYP1A1m2 GSTM1 GSTT1
CYP1A1m1 1 −0.005 −0.123 −0.074
– 0.935 0.054 0.250
CYP1A1m2 −0.005 1 0.152a −0.167b
0.935 – 0.017 0.009
GSTM1 −0.123 0.152a 1 −0.047
0.054 0.017 – 0.465
GSTT1 −0.074 −0.167b −0.047 1
0.250 0.009 0.465 –
Table 9 Association of  superoxide dismutase levels in  relation to  CYP1A1 and  GST gene polymorphisms in  NSCLC 
patients and healthy controls
* p < 0.05
Gene Genotype Lung cancer patients  
(SOD levels)
p value Controls (SOD levels) p value Total p value
n Mean ± SE n Mean ± SE
CYP1A1, m1 T/T 121 914.28 ± 30.05 138 1166.08 ± 12.8 0.92
T/C 89 915.73 ± 17.03 0.45 98 1165.71 ± 13.93 0.35 0.14
C/C 28 910.74 ± 13.57 0.62 14 1070.00 ± 37.60 0.78 0.65
CYP1A1, m2 A/A 71 922.25 ± 18.18 196 1190.00 ± 10.61 <0.01*
A/G 156 909.87 ± 12.00 0.81 34 1165.91 ± 20.61 0.14 0.05*
G/G 11 898.18 ± 67.01 0.07 20 1080.58 ± 23.82 0.08 0.02*
GSTM1 +/+ 174 927.01 ± 11.81 187 1214.54 ± 7.47 <0.01*
–/– 64 875.00 ± 18.00 0.56 63 1175.71 ± 10.72 0.15 <0.01*
GSTT1 +/+ 192 929.58 ± 10.57 224 1168.03 ± 9.86 0.91
–/– 46 843.91 ± 24.69 0.04* 26 1096.12 ± 23.16 0.10 0.05*
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Discussion
Xenobiotic metabolising enzymes expedites purging 
of a variety of toxic substances, thereby gaining promi-
nence in the pathophysiology of cancer. Hence, gene 
polymorphisms in the enzymes that are intricate in the 
metabolism of carcinogens may regulate an individu-
al’s predisposition to cancer including lung cancer [36]. 
Besides this, environmental and life style insults also 
contribute to the predisposition of lung cancer. Cigarette 
smoke contain PAHs which can be metabolically acti-
vated to highly reactive compounds capable of binding 
to DNA and initiating the carcinogenic process [37, 38]. 
Among the variety of xenobiotic metabolising enzymes, 
CYP1A1, GSTM1 and GSTT1 have been implicated to 
modulate the risk of lung cancer because of their poten-
tial involvement in carcinogenesis metabolism. Globally 
many studies reported on the association among gene 
interactions and lung cancer in different populations, but 
the conclusions were conflicting [18]. In the Indian con-
text, risk assessment between gene polymorphisms and 
lung cancer was investigated in Northern and Southern 
Indian populations. CYP1A1, GSTM1 and GSTT1 poly-
morphisms and the association with lung cancer in the 
South Indian population (patients reporting to a spe-
cific hospital in Thiruvananthapuram, the capital city of 
Kerala state) was reported [30], suggesting the risk in the 
specific population of that state. However, there are geno-
typic, life style and environmental differences in the pop-
ulations of the five states (Andhra Pradesh, Tamilnadu, 
Kerala, Karnataka and Maharashtra) of South India. 
Hence, we conducted systematic analyses on the asso-
ciations of CYP1A1, GSTM1 and GSTT1 polymorphisms 
Table 10 Association of  glutathione peroxidase activity in  relation to  CYP1A1 and  GST gene polymorphisms in  NSCLC 
patients and healthy controls
* p < 0.05
Gene Genotype Lung cancer patients  
(GPx levels)
p value Controls (GPx levels) p value Total p value
n Mean ± SE n Mean ± SE
CYP1A1 m1 T/T 121 47.51 ± 4.52 138 55.44 ± 0.60 <0.01*
T/C 89 45.77 ± 2.45 0.01* 98 55.15 ± 0.69 0.74 <0.01*
C/C 28 43.42 ± 2.02 <0.01* 14 51.42 ± 1.74 0.79 0.06
CYP1A1 m2 A/A 71 48.18 ± 6.45 196 59.35 ± 0.33 <0.01*
A/G 156 44.02 ± 1.75 <0.01* 34 55.26 ± 0.65 0.17 <0.02*
G/G 11 45.94 ± 2.93 0.01* 20 54.67 ± 0.91 0.53 <0.01*
GSTM1 +/+ 174 46.22 ± 1.74 187 57.69 ± 0.36 <0.01*
–/– 64 40.87 ± 2.69 0.33 63 54.41 ± 0.84 0.21 <0.01*
GSTT1 +/+ 192 46.66 ± 1.53 224 55.50 ± 0.47 <0.001*
–/– 46 36.95 ± 3.95 0.05* 26 51.69 ± 1.12 0.07 <0.001*
Table 11 Association of  Lipid peroxidation (MDA) levels in  relation to  CYP1A1 and  GST gene polymorphisms in  NSCLC 
patients and healthy controls
* p < 0.05
Gene Genotype Lung cancer patients  
(MDA levels)
p value Controls (MDA levels) p value Total p value
n Mean ± SE n Mean ± SE
CYP1A1 m1 T/T 127 4.18 ± 0.24 138 1.72 ± 0.10 0.01*
T/C 90 4.21 ± 0.13 <0.01* 98 1.79 ± 0.24 0.42 <0.01*
C/C 29 4.30 ± 0.13 <0.01* 14 2.00 ± 0.42 0.83 <0.01*
CYP1A1 m2 A/A 73 4.23 ± 0.15 196 1.56 ± 0.11 0.07
A/G 162 4.22 ± 0.11 0.39 34 1.75 ± 0.23 0.34 0.79
G/G 11 4.52 ± 0.39 0.87 20 2.12 ± 0.28 0.29 0.86
GSTM1 +/+ 182 4.11 ± 0.10 187 1.73 ± 0.03 <0.01*
–/– 64 4.60 ± 0.13 0.02* 63 1.95 ± 0.71 0.21 <0.001*
GSTT1 +/+ 200 4.06 ± 0.09 224 1.75 ± 0.29 <0.001*
–/– 46 5.00 ± 0.20 0.31 26 1.91 ± 0.12 0.09 <0.01*
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with the risk of NSCLC in the population of Andhra 
Pradesh.
In the present study, a high frequency of CYP1A1 m1 
homozygous minor genotype (C/C) was recorded among 
NSCLC patients. Association of lung cancer risk with 
homozygosity of CYP1A1 variant alleles was reported in 
Chilean and Caucasian populations [39–41]. Likewise, 
in the North and South Indian populations, the asso-
ciation of CYP1A1 polymorphism with lung cancer risk 
was reported [30, 42, 43]. Further, in the current study, 
evaluation of the genotypic frequencies in lung can-
cer patients from Andhra Pradesh have shown a higher 
Table 12 Urinary 8-OHdG levels (ng/mg creatinine) in  relation to  CYP1A1 and  GST gene polymorphisms in  NSCLC 
patients and healthy controls
* p < 0.05
# yates corrected Chi square
Gene Genotype Lung cancer patients  
(8‑OhdG levels)
p value Controls (8‑OhdG levels) p value Total p value
n Mean ± SE n Mean ± SE
CYP1A1 m1 T/T 64 6.03 ± 0.09 57 4.22 ± 0.10 0.71
T/C 45 6.08 ± 0.12 0.41 37 4.44 ± 0.11 0.44 0.25
C/C 16 6.11 ± 0.23 0.18 6 4.50 ± 0.19 0.27 0.13
CYP1A1 m2 A/A 41 5.91 ± 0.21 79 4.28 ± 0.17 0.42
A/G 78 6.03 ± 0.09 0.007* 17 4.37 ± 0.17 0.47 0.58
G/G 6 6.13 ± 0.13 0.04* 4 4.75 ± 0.19 0.45 0.67#
GSTM1 +/+ 102 5.97 ± 0.78 71 4.26 ± 0.85 0.39
–/– 23 6.43 ± 0.16 0.60 29 4.61 ± 0.10 0.28 0.07
GSTT1 +/+ 101 5.88 ± 0.69 88 4.23 ± 0.64 0.16
–/– 24 6.82 ± 0.17 0.02* 12 5.35 ± 0.10 0.63 0.04*
Table 13 Multiple regression analysis of different variants in NSCLC
a Slope of the regression line
b Standard error of the regression line
* p < 0.05
Variable Unstandardised coeeficients Standardized coefficients t Sig. 95 % confidence interval for B
Lower bound Upper boundBa Standard errorb
Age 0.001 0.001 0.012 1.241 0.216 0.000 0.002
Sex −0.017 0.014 −0.015 −1.245 0.215 −0.044 0.010
Smoking −0.005 0.008 −0.009 −0.624 0.034* −0.021 0.011
Passive smoking −0.003 0.018 −0.002 −0.165 0.869 −0.038 0.032
Histology −0.049 0.009 −0.094 −5.402 0.000* −0.067 −0.031
Stage −0.173 0.017 −0.463 −9.935 0.000* −0.207 −0.138
Alcohol 0.007 0.011 0.007 0.639 0.523 −0.015 0.030
Diet −0.001 0.013 −0.001 −0.063 0.950 −0.026 0.025
Place of living −0.004 0.006 −0.007 −0.666 0.506 −0.015 0.007
Familial −0.018 0.023 −0.008 −0.769 0.443 −0.063 0.027
MDA 0.026 0.013 0.083 1.991 0.048* 0.000 0.052
GPx −0.005 0.001 −0.199 −9.468 0.000* −0.006 −0.004
SOD −0.005 0.000 0.012 0.494 0.622 0.000 0.000
8-OHdG 0.019 0.012 0.045 1.622 0.106 −0.004 0.043
CYPM1 −0.003 0.007 −0.003 −0.376 0.007* −0.016 0.011
CYPM2 −0.002 0.008 −0.003 −0.268 0.789 −0.019 0.014
GSTM1 −0.008 0.015 −0.006 −0.512 0.609 −0.037 0.022
GSTT1 −0.020 0.018 −0.014 −1.072 0.025* −0.056 0.017
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frequency and a significant association of CYP1A1 m2 
heterozygous ‘AG’ genotype. Similar observations (higher 
frequency of CYP1A1 m2 (A/G) allele) were reported in 
lung cancer patients from Korea [19]. On the same lines, 
CYP1A1 m2 (G/G) allele frequency was demonstrated to 
be lower in Caucasians than Japanese [44]. Heterozygous 
and homozygous minor CYP1A1 m2 genotypes were on 
the higher side in Chilean lung cancer patients [25]. The 
higher frequency of this gene was also reported in the 
Southern and Northern Indian lung cancer patients [42, 
45]. Results of our study are in parallel with the observa-
tions made in different populations worldwide, and it is 
possible that the mutated genotype of CYP1A1 plays an 
important role in the aetiology of lung cancer in the pop-
ulation of Andhra Pradesh state.
In the current study, GSTM1 wild and null geno-
types were detected, respectively, in 73.98 and 26.1 % of 
lung cancer patients. A similar trend was observed in 
the healthy controls (76 % wild type and 24 % null type, 
respectively). Similarly, GSTM1 null genotype was not 
associated with the increased risk of lung cancer, and 
the proportions of the NSCLC patients and healthy con-
trols exhibiting GSTM1 null genotype were apparently 
equal. Similar trends were observed in the South and 
North Indian population cohorts [30, 46]. On the con-
trary, GSTM1 null or deletion genotype was reported to 
be prevalent in about 50 % of Caucasians, 33 % of African 
Americans and 45 % of Japanese [47] lung cancer patients. 
We found that GSTT1 null genotype was high in lung 
cancer patients compared to the controls, which is con-
sistent [30, 41, 48] and in conflict [42, 49] with previous 
reports. GSTT1 deletion polymorphisms was reported 
in 13–28 % of Caucasians [18]. Similarly, the frequencies 
of homozygous deletions (null genotype) for GSTM1 and 
GSTT1 were found to be 22.4 % and 17.6 %, respectively, 
in the South Indian population; 54  % and 13  %, respec-
tively, in the East Indian population [50, 51]; 41  % and 
21.5 %, respectively, in the North Indian population [46]. 
Results of our study and others indicate that in the Indian 
context, the risk of lung cancer is more associated with 
GSTT1 polymorphism rather than GSTM1 genotype.
A majority of the patients included in our study were 
bidi smokers (made of crude particles of dried tobacco 
leaves wrapped in a tendu or temburni leaf and rich in 
tar and nicotines); and bidi smoking is known to gener-
ate stronger carcinogen load than cigarette [52]. Our 
data clearly indicate that individuals who were smokers 
and had CYP1A1m1 T/C, C/C or CYP1A1m2 A/G, G/G 
genotypes and GSTT1 null genes were at higher risk of 
disease susceptibility to lung cancer. A threefold risk of 
lung cancer associated with CYP1A1 m1 genotype was 
reported [46]. Further, increased risk of lung cancer in 
heavy smokers [34, 42] and light smokers [20, 53] with 
CYP1A1 m1 allele was demonstrated. In the present 
study, no risk of lung cancer was associated with GSTM1 
null genotype in smokers and non-smokers. The associa-
tion between GSTM1 genotype and cumulative smoking 
is controversial [47]. Stronger associations were reported 
in casual smokers [42] and low smoking exposed indi-
viduals [53], whereas such an association was not evident 
in other reports [54]. Results of our study indicate that 
CYP1A1 polymorphisms rather than GSTM1 polymor-
phisms and smoking contribute to the higher risk of lung 
cancer. Our results are in accordance with another study 
from North India where the relative risk for the carriers 
of variant CYP1A1 genotypes was high [55]. The disease 
association among combination of GST genes in the 
lung cancer patients was found between the Wild/Null 
and Null/Null types. The increased risk due to deletions 
of GST may result in less detoxification of xenobiotics, 
thereby making the individual more susceptible to toxic 
substances present in the environment.
Analysing multiple gene interactions provide better 
understanding to assess the risks associated with lung can-
cer risk. In our study, the combinations of two (CYP1A1 
m2 and GSTM1) or three (CYP1A1 m1, CYP1A1 m2 and 
GSTM1/GSTT1) genotypes had a profound effect on sus-
ceptibility to lung cancer up to 14-fold depending on the 
genotypic interaction. Correlations between lung cancer 
risk and combinations of CYP1A1, GSTM1 and GSTT1 
is of particular interest since these genotypes suggest that 
alterations in the action of phases I and II enzymes lead to 
defective metabolism of xenobiotic compounds, thereby 
potentiating the cancer risk. It was suggested that indi-
viduals having polymorphisms in more than one of these 
genes are at higher risk than having for only one gene [56]. 
Polymorphisms of MspI and exon7-Val of CYP1A1 and 
GSTM1 null genotypes and increased lung cancer risk 
was evidenced in summarized data of 46 studies of Chi-
nese populations [56]. In an Indian population study, a 
twofold risk of lung cancer was found in individuals dis-
playing variations in the CYP1A1 and GSTM1 genes [42]. 
CYP1A1, GSTM1, GSTP1 and GSTT1 polymorphisms 
and their association to lung cancer in a cohort of North 
Indian population was reported [46]. Similarly, in a study 
involving South Indian population, a 4.4-fold increased 
risk of the GSTM1 null, GSTT1 null, CYP1A1 homozygous 
major genotype combination and a 3.5-fold increased risk, 
although not statistically significant, in individuals pos-
sessing the GSTM1 null, GSTT1 null, CYP1A1 homozy-
gous minor genotype combination [30, 57] were reported. 
Results of our study are in agreement with the reported 
data and clearly indicate strong associations of CYP1A1, 
GSTM1 and GSTT1 genetic polymorphism with NSCLC.
The role of oxidative stress in the pathophysiology 
of a variety of cancers including lung cancer was well 
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documented [32]. Genetic polymorphisms of metabolic 
enzymes and oxidative stress markers in occupational 
exposure were reported [58]. However, the association 
between oxidative stress and genetic polymorphisms with 
respect to lung cancer was not documented. We previously 
demonstrated that 8-oxo-dG and malondialdehyde levels 
were increased and red cell superoxide dismutase and glu-
tathione peroxidase activities were significantly decreased 
in lung cancer patients [32]. Hence, in this study, the geno-
types of polymorphic markers were stratified with respect 
to oxidative markers to evaluate whether the inter-indi-
vidual variation of oxidants and antioxidants could lead to 
disease susceptibility. To the best of our knowledge, this is 
the first study to assess the association of polymorphism of 
CYP1A1 and GST genes with respect to SOD, GPx, MDA 
and 8-oxo-dG levels in lung cancer patients from India. We 
found an association between GSTT1 null genotype and 
SOD activity, CYP1A1 m1, m2 and GSTT1 and GPx activ-
ity, MDA levels and CYP1A1 m1 & GSTM1, 8-oxo-dG and 
CYP1A1 m1 and GSTT1 gene polymorphisms. Although 
no information is available on the association of oxidants, 
antioxidants and gene polymorphisms, some information 
is available on the association of gene polymorphisms and 
urinay 8-oxo-dG levels. While some studies [59–65] dem-
onstrated the influence of gene polymorphisms on urinary 
8-oxo-dG levels, some other studies did not show such an 
association [66–68]. It is possible that deletion polymor-
phisms of GSTM1 and GSTT1 (null genotype) results in 
no functional enzymatic activity, thereby failing to detoxify 
several xenobiotics including tobacco smoke constituents 
and finally leading to increased generation of ROS and 
lowered GPx activity and O−
2
 scavenging activity of SOD. 
Results of our study provide strong association between 
gene polymorphisms, oxidant and antioxidant status and 
the risk of developing NSCLC, which hitherto was not 
reported.
The limitations of our study are that the healthy con-
trols and NSCLC patients were in the ratio of 1:1, and 
some of the NSCLC patients had co-morbid conditions. 
Further studies with large sample size can provide con-
crete data on the combined effect of genetic polymor-
phisms and NSCLC. The effect of co-morbid conditions 
to the contribution of gene polymorphisms observed 
cannot be ruled out.
In conclusion, we report that in the population of 
Andhra Pradesh, the South Indian state, a higher risk of 
lung cancer was associated with combined gene poly-
morphisms of phase I and phase II enzymes, than with 
a single susceptible gene. Risk assessment of NSCLC can 
be related to gene polymorphisms and oxidant status. 
This finding may have an important implication for the 
prevention of smoking and occupational exposures in 
susceptible individuals.
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